97.98MMarket Cap-0.79P/E (TTM)
4.7500High4.0800Low270.09KVolume4.3600Open4.4000Pre Close1.23MTurnover2.07%Turnover RatioLossP/E (Static)20.80MShares20.900052wk High0.68P/B61.52MFloat Cap3.520052wk Low--Dividend TTM13.06MShs Float624.8000Historical High--Div YieldTTM15.23%Amplitude3.5200Historical Low4.5440Avg Price1Lot Size
Adverum Biotechnologies Stock Forum
📊⚡️📊
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...
No comment yet